Michael Anstey

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTAC® and TRIMGLUE®. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of body’s own proteins to form amyloid deposits in vital organs. Immutrin Ltd is a Cambridge-based biotech company that is generating transformative antibody treatments for systemic and local amyloidosis.

Innovate Cambridge is leading an inclusive, forward looking and ambitious innovation roadmap for Cambridge. Cambridge is the best-positioned ecosystem in the UK to drive prosperity through economic growth, solve local issues and tackle global challenges thanks to the innovation community that has been cultivated and supported in the city. The Innovate Cambridge strategy, underpinned by a partnership with over 200 organisations and Charter Signatories and over 500 key stakeholders, aims to ensure that Cambridge’s science, innovation and business communities have what they need to be successful, maximising economic and social return and sharing that growth with the wider community and the UK. This includes nurturing people who will deliver pioneering discoveries; translating ideas into successful businesses; collaborating outside and within the region to amplify impact; and leading on sustainable, inclusive and green growth.

A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.

Cambridge& is a not-for-profit company. We incorporated in 2020 and launched in 2021. Our aim is to attract the highest quality individuals and organisations in the knowledge intensive industries from around the globe into our ecosystem. Our key roles are to: • promote and support the sustainable growth of Greater Cambridge • serve and collaborate with the existing networks and stakeholders by identifying and pursuing globally minded innovation, science and technology businesses to set up or grow in Cambridge, attracting those firms that complement and strengthen the ecosystem, enhancing the Quality of Life of the region Cambridge& is formally supported by a range of significant stakeholders: the University of Cambridge, the Greater Cambridge Partnership, Cambridge Innovation Capital, Taylor Wessing, Deloitte and Lexington Communications. Its creation has been developed through deep collaboration with key business organisations, academia and the civic community. It has seen the drawing together of each crucial segment of our ecosystem in support of Cambridge&. The consequences are expected to be many fold - increasing high quality international investment and encouraging a larger pool of significant talent and skills. Crucially, given the unique nature of Cambridge, our success will benefit all those living and working in the region, and the wider UK economy. We work collaboratively with many established networks in the ecosystem. We aim to promote a model example of a coordinated, outward, globally facing Cambridge, celebrating the pride we have in our ecosystem and the diversity of our talent.

PredictImmune develops pioneering tools for guiding personalised treatment options in immune-mediated diseases such as inflammatory bowel disease (IBD). Based on world-leading research at Cambridge University, UK, we are developing a simple lab test, using a small blood sample, which accurately identifies patients at diagnosis who are at risk of experiencing severe, relapsing disease. These patients are likely to benefit from early biologics therapy. Physicians, patients and payers all recognise the value of such an approach to the management of inflammatory bowel disease (IBD). www.predictimmune.com

Sense is transforming healthcare by redefining diagnostics. Founded in 2014, we strive to improve lives by bringing powerful tools for fast, accurate, and accessible diagnostics to all. We’re focused on creating a portfolio of unconstrained, instrument-free molecular diagnostic technologies. Our Veros™ platform introduces novel and proprietary rapid molecular amplification technology to detect a variety of deadly and costly diseases. We’re developing technologies that combine the power of laboratory tests with the simplicity and ease of use of products because we believe that if you can test anywhere, you can change everything.* *Professional use, patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

We are a #Cambridge, UK based #healthcare & #lifesciences investor and venture builder developing #startups that are built to succeed globally.

STORM Therapeutics is a biotechnology company creating novel therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. There are more than 150 RNA modifications reported and approximately 300 RNA modifying enzymes which represent novel therapeutic targets. STORM has leveraged its first mover advantage to establish a novel drug discovery and RNA analytics platform leading to the identification of novel targets and a proprietary pipeline of first in class small-molecule drug candidates for potential use in oncology, inflammation, viral infections, and CNS diseases. The pipeline is exemplified by STORM’s METTL3 inhibitor (STC-15) for which an IND has been filed with the FDA to support initiation of a Phase I clinical trial in cancer patients in 2022. STC-15 represents the first RNA modifying enzyme inhibitor to enter clinical evaluation in humans. Additional candidates are planned for advancement into IND-track activities in 2023. STORM has built an experienced R&D team who occupy modern, well-equipped laboratories on the Babraham Research Campus near Cambridge, UK. The company’s proprietary in house research is complemented by outsourcing of some discovery activities to high quality CRO partners (e.g., Evotec) enabling STORM to operate a cost efficient and flexible model.

Congenica is a digital health company providing software and solutions for the analysis and interpretation of genomic data at scale. We drive Precision Medicine and help reduce the burden on healthcare systems by delivering automated analysis, diagnosis and treatment solutions to healthcare providers and patients worldwide. Congenica’s Platform is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive for both rare diseases and somatic and inherited cancer, and is uniquely placed to drive ubiquitous use of complex data in routine clinical care. Our products and services are consolidated on one single scalable, automated analysis and diagnostic platform that encompasses inherited disease, somatic cancer, pharma insights and pathogen surveillance. Congenica was founded based on pioneering work at the Wellcome Trust Sanger Institute and the UK NHS. We are the exclusive clinical decision support partner for the NHS Genomic Medicine Service and have a global footprint supporting leading international laboratories, academic medical centres, hospitals and biopharmaceutical companies.

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.

TRIMTECH has a growing pipeline of potent, CNS (central nervous system) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTAC® and TRIMGLUE®. The pipeline is focused around the development of treatments for severe neurodegenerative and inflammatory disorders, including Alzheimer’s and Huntington’s disease.

At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

Amyloidosis is a group of rare but very serious, usually fatal diseases caused by the aggregation of body’s own proteins to form amyloid deposits in vital organs. Immutrin Ltd is a Cambridge-based biotech company that is generating transformative antibody treatments for systemic and local amyloidosis.

Innovate Cambridge is leading an inclusive, forward looking and ambitious innovation roadmap for Cambridge. Cambridge is the best-positioned ecosystem in the UK to drive prosperity through economic growth, solve local issues and tackle global challenges thanks to the innovation community that has been cultivated and supported in the city. The Innovate Cambridge strategy, underpinned by a partnership with over 200 organisations and Charter Signatories and over 500 key stakeholders, aims to ensure that Cambridge’s science, innovation and business communities have what they need to be successful, maximising economic and social return and sharing that growth with the wider community and the UK. This includes nurturing people who will deliver pioneering discoveries; translating ideas into successful businesses; collaborating outside and within the region to amplify impact; and leading on sustainable, inclusive and green growth.

A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.